Maze Therapeutics closed at $33.38 on Nov 4, up 3.50%, 35.6% below its 52-week closing high. Volume of 536.6K shares was 0.71× its 20-day average (below normal).
Split-adjusted performance: +26.3% over one month, +26.1% over six months, +0.4% over one year.
Short interest was 7.5M shares at the Oct 15 settlement, up 14.7% from the prior report (18.8% of float, 10.1 days to cover).
No reported quarters with price history yet.
Percentile among 139 companies (100 = best)
Industry medians: 6-month return −19.2%, revenue growth +8.8%, net margin −312.9%, P/E 22.0×.
| Company | Price | Today | 6M | Rev. growth | Net margin | P/E | Mkt cap | |
|---|---|---|---|---|---|---|---|---|
| MAZEMaze Therapeutics | $33.38 | +3.50% | +26.1% | — | — | — | $1.85B | |
| NVAXNovavax | $10.65 | +10.02% | +13.8% | −76.3% | −94.2% | — | $1.76B | Compare |
| REPLReplimune Group | $20.69 | +0.19% | +501.5% | — | — | — | $1.96B | Compare |
| VIRVir Biotechnology | $11.77 | +4.90% | +14.4% | +19582.5% | 33.5% | — | $1.99B | Compare |
| BCRXBioCryst Pharmaceuticals | $8.24 | −3.85% | −6.7% | +33.6% | 35.9% | — | $2.11B | Compare |
| COAGHemab Therapeutics Holdings | $45.09 | +4.62% | — | — | — | — | $2.11B | Compare |
| RXRXRecursion Pharmaceuticals | $3.88 | +5.43% | +13.1% | +258.5% | −641.6% | — | $2.32B | Compare |
| VCELVericel | $45.48 | +10.68% | +23.7% | +22.5% | 2.8% | 96.2 | $2.33B | Compare |
| ADMAADMA Biologics | $10.48 | −5.67% | +4.0% | +2.0% | 30.4% | 13.9 | $2.35B | Compare |
Maze Therapeutics Inc is a clinical-stage biopharmaceutical company harnessing the power of human genetics to develop novel, small-molecule precision medicines for patients living with renal, cardiovascular, and related metabolic, or CVRM, diseases, including obesity. The company is advancing a pipeline using its Compass platform, which allows the company to identify and characterize genetic variants in disease and then link those variants to the biological pathways that drive disease in specific patient groups through a process it refers to as variant functionalization. It is currently advancing two programs, MZE829 and MZE782, each of which represents a novel precision medicine-based approach for chronic kidney disease, or CKD.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology
